Tucatinib in Combination With Oral Etoposide andTrastuzumab in Patients With Metastatic HER2+ Breast Cancer
Status:
Recruiting
Trial end date:
2027-12-19
Target enrollment:
Participant gender:
Summary
This is an open-label, multicenter, phase II study to evaluate the efficacy, safety,
tolerability, pharmacokinetics of the combination of tucatinib-Oral VP16-trastuzumab in
patients with HER2-positive metastatic breast cancer (HER2+ MBC) after progression on
tucatinib-capecitabine-trastuzumab or capecitabine-related toxicity.